Enhanced in vivo retention of low dose BMP-2 via heparin microparticle delivery does not accelerate bone healing in a critically sized femoral defect
- 1 September 2017
- journal article
- Published by Elsevier in Acta Biomaterialia
- Vol. 59, 21-32
Abstract
No abstract availableKeywords
This publication has 49 references indexed in Scilit:
- Hyaluronic acid-based hydrogels functionalized with heparin that support controlled release of bioactive BMP-2Biomaterials, 2012
- Functional Restoration of Critically Sized Segmental Defects With Bone Morphogenetic Protein-2 and Heparin TreatmentClinical Orthopaedics and Related Research, 2011
- Affinity-based growth factor delivery using biodegradable, photocrosslinked heparin-alginate hydrogelsJournal of Controlled Release, 2011
- Effects of protein dose and delivery system on BMP-mediated bone regenerationBiomaterials, 2011
- The effect of immobilization of heparin and bone morphogenic protein-2 (BMP-2) to titanium surfaces on inflammation and osteoblast functionBiomaterials, 2011
- An alginate-based hybrid system for growth factor delivery in the functional repair of large bone defectsBiomaterials, 2011
- Bone morphogenic protein-2 (BMP-2) loaded nanoparticles mixed with human mesenchymal stem cell in fibrin hydrogel for bone tissue engineeringJournal of Bioscience and Bioengineering, 2009
- Complications of Recombinant Human BMP-2 for Treating Complex Tibial Plateau Fractures: A Preliminary ReportClinical Orthopaedics and Related Research, 2009
- Bone morphogenetic protein-2 but not bone morphogenetic protein-4 and -6 stimulates chemotactic migration of human osteoblasts, human marrow osteoblasts, and U2-OS cellsBone, 1996
- Cell surface thrombospondin is functionally essential for vascular smooth muscle cell proliferationJournal of Cell Biology, 1988